These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 17460700)
1. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Kline MP; Rajkumar SV; Timm MM; Kimlinger TK; Haug JL; Lust JA; Greipp PR; Kumar S Leukemia; 2007 Jul; 21(7):1549-60. PubMed ID: 17460700 [TBL] [Abstract][Full Text] [Related]
2. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson KC Oncogene; 2007 Apr; 26(16):2374-80. PubMed ID: 17016430 [TBL] [Abstract][Full Text] [Related]
3. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285 [TBL] [Abstract][Full Text] [Related]
4. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics. Karlberg M; Ekoff M; Huang DC; Mustonen P; Harvima IT; Nilsson G J Immunol; 2010 Aug; 185(4):2555-62. PubMed ID: 20639495 [TBL] [Abstract][Full Text] [Related]
5. The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells. Allaman-Pillet N; Oberson A; Munier F; Schorderet DF Ophthalmic Genet; 2013; 34(1-2):1-13. PubMed ID: 21955141 [TBL] [Abstract][Full Text] [Related]
6. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells]. Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096 [TBL] [Abstract][Full Text] [Related]
7. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Tagscherer KE; Fassl A; Campos B; Farhadi M; Kraemer A; Böck BC; Macher-Goeppinger S; Radlwimmer B; Wiestler OD; Herold-Mende C; Roth W Oncogene; 2008 Nov; 27(52):6646-56. PubMed ID: 18663354 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells. Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104 [TBL] [Abstract][Full Text] [Related]
10. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200 [TBL] [Abstract][Full Text] [Related]
11. The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL. Ezzoukhry Z; Louandre C; François C; Saidak Z; Godin C; Mazière JC; Galmiche A Mol Pharmacol; 2011 Jun; 79(6):997-1004. PubMed ID: 21393385 [TBL] [Abstract][Full Text] [Related]
12. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Huang S; Sinicrope FA Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764 [TBL] [Abstract][Full Text] [Related]
13. Targeting multiple arms of the apoptotic regulatory machinery. Dai Y; Grant S Cancer Res; 2007 Apr; 67(7):2908-11. PubMed ID: 17409392 [TBL] [Abstract][Full Text] [Related]
14. Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad. Yin S; Dong Y; Li J; Fan L; Wang L; Lu J; Vang O; Hu H Apoptosis; 2012 Apr; 17(4):388-99. PubMed ID: 22179721 [TBL] [Abstract][Full Text] [Related]
15. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435 [TBL] [Abstract][Full Text] [Related]
16. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy. Karlsson H; Lindqvist AC; Fransson M; Paul-Wetterberg G; Nilsson B; Essand M; Nilsson K; Frisk P; Jernberg-Wiklund H; Loskog A Cancer Gene Ther; 2013 Jul; 20(7):386-93. PubMed ID: 23788110 [TBL] [Abstract][Full Text] [Related]
17. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698 [TBL] [Abstract][Full Text] [Related]
18. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671 [TBL] [Abstract][Full Text] [Related]
19. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer. Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity. Zheng CH; Yang H; Zhang M; Lu SH; Shi D; Wang J; Chen XH; Ren XH; Liu J; Lv JG; Zhu J; Zhou YJ Bioorg Med Chem Lett; 2012 Jan; 22(1):39-44. PubMed ID: 22172701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]